Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence
- PMID: 32451316
- DOI: 10.1016/j.euf.2020.04.011
Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence
Abstract
The role of neoadjuvant chemotherapy in variant histology bladder cancers has yet to be validated in randomized control trials. Several case series have reported experience with NAC in the setting of variant histology. PATIENT SUMMARY: We reviewed outcomes for patients with variant histology muscle-invasive bladder cancer who received chemotherapy before cystectomy. Outcomes varied significantly in the current literature. The best outcomes are associated with neoadjuvant chemotherapy (NAC) for small cell variants, while there is potential benefit with the use of NAC for squamous cell and adenocarcinoma variants.
Keywords: Bladder cancer; Micropapillary; Neoadjuvant chemotherapy; Neuroendocrine; Outcomes; Variant histology.
Copyright © 2020. Published by Elsevier B.V.
Comment in
-
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639-41.Eur Urol Focus. 2021 Nov;7(6):1506-1507. doi: 10.1016/j.euf.2020.08.006. Epub 2020 Sep 3. Eur Urol Focus. 2021. PMID: 32891585 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
